Resmed Inc. Stock
Price
Target price
€187.90
€187.90
-1.850%
-3.5
-1.850%
€258.40
23.04.26 / Tradegate
WKN: 895878 / Symbol: RMD / Name: ResMed / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Resmed Inc. Stock
A loss of -1.850% shows a downward development for Resmed Inc..
We see a rather positive sentiment for Resmed Inc. with 20 Buy predictions and 1 Sell predictions.
As a result the target price of 258 € shows a positive potential of 37.31% compared to the current price of 187.9 € for Resmed Inc..
Pros and Cons of Resmed Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | -1.850% | -1.494% | -4.279% | -0.740% | -9.880% | -9.489% | 8.425% |
| Veeva Systems A | -4.610% | -6.147% | -16.264% | -31.346% | -30.235% | -20.853% | -42.389% |
| Thermo Fisher Scientific Inc. | -8.950% | -8.815% | -3.083% | 4.817% | -19.203% | -23.241% | -1.041% |
| Waters Corp. | -7.070% | -1.771% | 2.385% | -9.885% | -18.792% | -4.929% | 4.803% |
Comments
ResMed (RMD) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (RMD) was given a new $255.00 price target by Evercore Inc. They now have an "outperform" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (RMD) had its price target lowered by Citigroup Inc. from $345.00 to $340.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
News
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
